Amgen Inc. SEC filings document the regulatory record for a Nasdaq-listed biotechnology company with common stock and registered debt securities. Its 8-K reports cover quarterly and annual earnings releases, Regulation G reconciliations for non-GAAP measures, free cash flow disclosures, material definitive agreements, executive leadership changes and capital markets transactions.
The company's proxy materials describe annual meeting matters, board governance, executive compensation and stockholder voting procedures. Other filings address senior note offerings under registration statements and indentures, Nasdaq listing and registration matters for debt securities, and formal exhibits that define the terms of financing, governance and corporate disclosure events.
Amgen Inc. is asking stockholders to vote at its May 19, 2026 virtual annual meeting on four items: electing 12 directors, an advisory “Say on Pay” vote, ratifying Ernst & Young as auditor for 2026, and a stockholder proposal for an independent board chair, which the Board recommends voting against.
The proxy highlights strong 2025 execution, including 10% year-over-year revenue and sales growth, record sales for 18 products, 14 products each exceeding $1 billion in sales, and five U.S. FDA approvals. Amgen reports 37% sales growth in its biosimilar portfolio to $3 billion and notes that more than 25% of revenue comes from non-U.S. markets.
The company is investing heavily in U.S. manufacturing, following a prior $1 billion North Carolina expansion with additional commitments of $900 million in Ohio and $650 million in Puerto Rico, aimed at boosting capacity, yields, and supply resilience. Executive pay is described as performance-based, with 80% of annual long-term equity awards tied to performance and a 2025 annual incentive plan payout at 136% of target based on financial and strategic results.
The Vanguard Group filed Amendment No. 11 on a Schedule 13G/A reporting 0 shares of Amgen Inc. common stock. The filing states that, following an internal realignment on 01/12/2026, certain Vanguard subsidiaries now report beneficial ownership separately pursuant to SEC Release No. 34-39538 (01/12/1998), and The Vanguard Group no longer is deemed to beneficially own securities held by those subsidiaries. The amendment lists Amount beneficially owned: 0 and Percent of class: 0%, with all voting and dispositive powers shown as 0.
Amgen Inc. executive Esteban Santos, EVP of Operations, reported an automatic share disposition tied to taxes rather than an open-market trade. On March 16, 2026, 5,621 shares of common stock were transferred at $366.21 per share to satisfy a tax liability by delivering securities.
After this transaction, Santos directly holds 82,404 common shares, which include 696 Dividend Equivalents that will pay out in shares as restricted stock units vest. He also has an additional indirect holding of 909.9928 shares through Amgen's 401(k) Plan stock fund.
AMGEN INC executive David M. Reese reported a compensation-related share disposition tied to tax obligations. On March 16, 2026, 6,022 shares of Amgen common stock were delivered at $366.21 per share to satisfy tax liability or exercise costs, a transaction coded as tax-withholding. Following this event, Reese directly held 41,787 Amgen shares. A portion of his position also reflects dividend equivalents credited to unvested restricted stock units that will be paid in shares as they vest.
Amgen Inc. senior vice president Derek Miller reported a routine tax-withholding transaction in company stock. On March 16, 2026, 1,616 shares of Amgen common stock were disposed of at $366.21 per share to satisfy tax obligations related to equity compensation. Following this withholding, Miller directly holds 12,173 shares, which include 197 dividend equivalents tied to unvested restricted stock units that will pay out in shares as they vest.
Amgen Inc. senior vice president of business development Rachna Khosla reported a tax-related share disposition on company stock. On March 16, 2026, 707 shares of Amgen common stock were withheld at a price of $366.21 per share to satisfy tax obligations, rather than sold in the open market.
After this tax-withholding disposition, Khosla directly holds 8,291 Amgen shares. This amount includes 120 Dividend Equivalents granted under Amgen’s 2009 equity incentive plan, which convert into common stock on a one-to-one basis as related restricted stock units vest.
Amgen Inc. senior vice president and chief compliance officer Nancy A. Grygiel reported a routine tax-related share withholding. On March 16, 2026, 787 shares of Amgen common stock were disposed of at $366.21 per share to satisfy tax obligations tied to equity compensation.
After this tax-withholding disposition, she directly holds 8,488 Amgen shares, which include 122 dividend equivalents that will pay out in shares as they vest. She also indirectly holds 106.1873 shares through the company’s 401(k) plan stock fund.
Amgen Inc. EVP & CFO Peter H. Griffith reported a Form 4 transaction showing a tax-related share disposition. On March 16, 2026, 5,748 shares of Amgen common stock were disposed of at $366.21 per share to satisfy tax obligations by delivering shares. After this withholding transaction, he directly holds 49,001 shares of common stock. His holdings include 756 Dividend Equivalents granted under Amgen’s equity incentive plan, which are paid out in shares on a one-for-one basis as related restricted stock units vest.
Amgen Inc. executive Jonathan P. Graham reported a routine tax-related share disposition. On this Form 4, 5,353 shares of Amgen common stock were withheld at $366.21 per share to satisfy tax obligations, rather than sold in the open market. After this withholding, he directly owns 39,267 shares. The reported holdings include 659 dividend equivalent units that will pay out in Amgen shares as related restricted stock units vest.